Generating destination analysis
Catalyst Play
Featured in “Three Gene-Editing Stocks to Own Before Biotech's Fall 2026 Catalyst Wave”
Recursion Pharmaceuticals uses AI to discover drugs at a fraction of the usual cost and time, with multiple programs reading out. A risk-on biotech tape rewards the platform with the most shots on goal — and Recursion has more than almost anyone in the space.
The catalyst: The back half of 2026 is one of the most catalyst-dense stretches biotech has seen in years. The ESMO oncology congress and the ASH hematology meeting both land in the autumn, and the FDA's decision calendar is stacked — including a closely watched November 14 PDUFA date for ivonescimab in lung cancer. Clusters like this drive sector-wide risk-on, and capital flows first to the platforms with the deepest pipelines and clearest readouts. These three sit at the center of genetic medicine.
Compass Direction
Earnings IntelligenceAI-Powered
Compass Score
Key Numbers
Market Cap
$4B
P/E
N/A
Revenue Growth
+55.0%
Gross Margin
N/A
ROE
N/A
About Recursion Pharmaceuticals
Listed on the NASDAQ, Recursion Pharmaceuticals operates as a small-cap player in the biotech sector, offering investors focused access to biotech and genomics growth drivers. AI-driven drug discovery platform using machine learning to decode biology at scale. With a $4B market capitalization and no current profitability, the business is characterized by exceptional revenue growth, reporting +55% revenue change year-over-year.
Expert Coverage
Unlock Full RXRX Analysis
Expert analysis and coverage for Recursion Pharmaceuticals
Or unlock everything now with Compass, $9/moPrice & Technical Analysis
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
More in Biotech & Genomics
Eli Lilly and Company
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Regeneron Pharmaceuticals
Biotech powerhouse with strong antibody pipeline and Dupixent franchise.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.